The analyst rating for FOSUN PHARMA was raised to "Outperform" by CLSA due to the company's collaboration agreement with Pfizer for its preclinical small molecule GLP-1 drug, YP05002. The report highlighted Pfizer's active involvement and long-term commitment in the GLP-1 field, positioning YP05002 favorably in the market. Additionally, CLSA found the financial terms of the collaboration to be reasonable compared to similar agreements. As a result, CLSA increased its earnings forecasts for FOSUN PHARMA and raised its target prices for the company's shares.
